Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Trial of the Long-term Clinical Effects of Raising HDL Cholesterol With Extended Release Niacin/Laropiprant
Brief Summary: The primary aim is to assess the effects of raising HDL cholesterol (the good type) with extended release niacin/laropiprant 2g (previously known as MK-0524A) versus matching placebo on the risk of heart attack or coronary death, stroke, or the need for arterial bypass procedures (revascularisation) in people with a history of circulatory problems. The secondary aim is to assess the effects of extended release niacin/laropiprant 2g daily on heart attack, coronary death, stroke, and revascularisation separately and to assess the effects on mortality both overall and in various categories of causes of death, and of the effects on major cardiovascular events in people with a history of different diseases at the beginning of the study.


Options:
A: Arm Label: ER niacin/laropiprant; Type: EXPERIMENTAL; Interventions: Drug: ER niacin/laropiprant, Drug: simvastatin, Drug: ezetimibe/simvastatin | Arm Label: Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: simvastatin, Drug: ezetimibe/simvastatin | Intervention Type: DRUG; Name: ER niacin/laropiprant; Assigned to Arm(s): ER niacin/laropiprant | Intervention Type: DRUG; Name: simvastatin; Assigned to Arm(s): ER niacin/laropiprant, Placebo | Intervention Type: DRUG; Name: ezetimibe/simvastatin; Assigned to Arm(s): ER niacin/laropiprant, Placebo
B: Arm Label: ezetimibe/simvastatin; Type: EXPERIMENTAL; Interventions: Drug: ezetimibe/simvastatin, Drug: Placebo for simvastatin 40 mg | Arm Label: simvastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: simvastatin, Drug: Placebo for simvastatin 40 mg, Drug: Placebo for ezetimibe 10 mg/simvastatin 40 mg combination | Intervention Type: DRUG; Name: ezetimibe/simvastatin; Assigned to Arm(s): ezetimibe/simvastatin | Intervention Type: DRUG; Name: simvastatin; Assigned to Arm(s): simvastatin | Intervention Type: DRUG; Name: Placebo for simvastatin 40 mg; Assigned to Arm(s): ezetimibe/simvastatin, simvastatin | Intervention Type: DRUG; Name: Placebo for ezetimibe 10 mg/simvastatin 40 mg combination; Assigned to Arm(s): simvastatin
C: Intervention Type: DRUG; Name: niacin (+) laropiprant (+) simvastatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Comparator: niacin (+) laropiprant; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Comparator: simvastatin; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebos | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Diet, Behavioral: Exercise, Other: Placebos | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: Diet, Behavioral: Exercise, Drug: Niacin, Other: Placebos | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Behavioral: Diet, Behavioral: Exercise, Drug: Fenofibrate, Other: Placebos | Arm Label: 5; Type: EXPERIMENTAL; Interventions: Behavioral: Diet, Behavioral: Exercise, Drug: Niacin, Drug: Fenofibrate | Intervention Type: BEHAVIORAL; Name: Diet; Assigned to Arm(s): 2, 3, 4, 5 | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): 2, 3, 4, 5 | Intervention Type: DRUG; Name: Niacin; Assigned to Arm(s): 3, 5 | Intervention Type: DRUG; Name: Fenofibrate; Assigned to Arm(s): 4, 5 | Intervention Type: OTHER; Name: Placebos; Assigned to Arm(s): 1, 2, 3, 4

Answer: A